Form F-6EF COMPASS Pathways plc/ADR Filed by: Citibank,N.A./ADR

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Form F-6EF COMPASS Pathways plc/ADR Filed by: Citibank,N.A./ADR

TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS)

May 13, 2026 3:34 PM EDT

TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).

The analyst comments "1Q26 R&D was $26.5MM (-11% q/q) and G&A was $16.4MM (+2% q/q). 1Q26 net loss was $91.2MM; EPS was $0.71. End of 1Q26 cash was $466MM; cash is expected to provide runway to 2028, including the anticipated commercial launch of '360 in TRD.

COMP360 Rolling NDA Started, Expected To Complete In Q4 After 26-Week Ph3 COMP006 Data In Early Q3

CMPS... More

BTIG Reiterates Buy Rating on Compass Pathways (CMPS)

May 13, 2026 2:33 PM EDT

BTIG analyst Thomas Shrader reiterated a Buy rating and $14.00 price target on Compass Pathways (NASDAQ: CMPS)

The analyst comments "Modest update with the new CNPV voucher potentially shortening the final step to approval after the filing is complete. We see that window as variable and mostly based on the political winds - which are strong tailwinds at the moment. The remaining clinical data from PART B of the 006 trial will help define the duration of response for patients after two doses. We see this data as potentially meaningful once there is a... More